Hot Life Science Investor Mandate 2: Russian Venture Capital Fund Looking Globally for Early Stage Therapeutics, Devices and Diagnostics

30 Oct

The venture capital fund of a large Russian conglomerate with additional representation in New York, Zurich, and the UK id exclusively focused on early stage life science companies. The fund can invest up to USD 5 million per company generally in seed and series A rounds. The firm is open to investing globally and is actively seeking new investment opportunities. 

The fund is primarily focused on early-stage therapeutics, diagnostics, and medical devices. However, the firm may consider health IT. For therapeutics, the firm is agnostic in terms of subsectors and indications however only looking for products in pre-clinical to early-clinical is. The firm is also agnostic in terms of subsector and indication for diagnostics and medical devices but again is only interested in the early stage.

The fund seeks a strong and entrepreneurial management team and seek a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: